Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Interest Income

Income earned on cash, deposits, and investments held by the company.

Amgen Inc.NASDAQ: AMGN

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income remains negative

Q2 FY2026 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $0.

Context

  • Interest income amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest income increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Income vs competitors

How AMGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Interest income amounts to 0.0% of revenue for AMGN, versus a peer median of 0.3%.
AMGN Competitors
Interest Income for AMGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$685M USD-37.7%+29.2%0.7%
PFEPfizer Inc.LTM Jun 2026$532M USD-9.1%+33.9%0.8%
AZNAstraZeneca PLCLTM Sep 2026$342.11M USD+13.7%+64.4%0.6%
MRKMerck & Co., Inc.LTM Jun 2026$200M USD-55.7%+29.8%0.3%
ABBVAbbVie Inc.LTM Sep 2026$198M USD-33.8%+12.7%0.3%
GSKGSK plcLTM Jun 2026£106M GBP+24.7%-4.5%0.3%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$101M USD——0.2%
LLYEli Lilly and CompanyLTM Jun 2026$65M USD-64.0%+34.6%0.1%
AMGNAmgen Inc.LTM Jun 2026$0 USD——0.0%
NVSNovartis AGLTM Jun 2026$0 USD—-0.2%0.0%
Peer median (excluding AMGN) —-33.8%+29.5%0.3%

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.98B26.32B28.19B33.42B36.74B
Cost of Revenue6.45B6.41B8.42B12.86B10.73B
Gross Profit19.53B19.92B19.78B20.57B26.01B
Gross Margin75.2%75.7%70.1%61.5%70.8%
Research & Development6.32B4.43B4.78B5.96B6.97B
Selling, General & Admin5.37B5.41B6.18B7.1B7.05B
Operating Expenses11.89B10.35B11.84B13.31B15.34B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
EBITDA11.3B12.17B14.8B13.36B16.9B
EBITDA Margin43.5%46.2%52.5%40.0%46.0%
Operating Income7.64B9.57B7.9B7.26B10.68B
Operating Margin29.4%36.3%28.0%21.7%29.1%
Interest Income00000
Interest Expense1.2B1.41B2.88B3.16B2.76B
Other Income / Expenses(938M)(2.22B)(42M)(2.65B)(1.7B)
Income Before Tax6.7B7.35B7.86B4.61B8.98B
Pre-Tax Margin25.8%27.9%27.9%13.8%24.4%
Income Tax Expense808M794M1.14B519M1.27B
Net Income5.89B6.55B6.72B4.09B7.71B
Net Margin22.7%24.9%23.8%12.2%21.0%
EPS (Basic)10.3412.1812.567.6214.33
EPS (Diluted)10.2812.1112.497.5614.23
Weighted Avg Shares570M538M535M541M538M
Weighted Avg Shares (Diluted)573M541M538M541M542M

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.